The ESC Congress 2014 was one of the largest meetings in the history of the society, with more than 30,300 delegates in attendance at 27 clinical Hot Line presentations; 15 clinical trial updates; 19 registry studies; 4 new guidelines; and 4597 abstracts presented. Cardiology Review profiles 7 presentations.
This is a time of great change and uncertainty on many fronts in health care, and in cardiology in particular. From new research casting doubts on previously promising procedures (eg, the results from the Symplicity HTN-3 trial released at the 2014 ACC meeting that called into question the usefulness of renal denervation for treating resistant hypertension) to the continued chaos and turmoil surrounding the implementation and future of the Affordable Care Act (ACA), it seems the news raises more questions than it answers.
In this edition of Clinical Forum, we asked 3 Cardiology Review editorial board members to comment on the role of beta-blockers in patients treated with primary percutaneous coronary intervention.